OFM
Omega Fund Management Portfolio holdings
AUM
$154M
This Quarter Return
-8.79%
1 Year Return
-32.78%
3 Year Return
+82.35%
5 Year Return
+29.08%
10 Year Return
+90.46%
AUM
$160M
AUM Growth
+$160M
(+19%)
Cap. Flow
+$50.2M
Cap. Flow
% of AUM
31.4%
Top 10 Holdings %
Top 10 Hldgs %
99.66%
Holding
12
New
1
Increased
–
Reduced
2
Closed
1
Top Buys
| 1 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$56.2M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$5.45M |
| 2 |
Nuvation Bio
NUVB
|
$466K |
| 3 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$21 |
Sector Composition
| 1 | Healthcare | 99.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCAX
1
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $56.2M | 35.09% | +2,204,650 | New | +$56.2M |
|
|
2
Nuvation Bio
NUVB
$1.02B
| $29.9M | 18.71% | 13,072,340 -203,544 | -2% | -$466K |
|
3
Replimune Group
REPL
$422M
| $27M | 16.86% | 2,461,319 | – | – |
|
4
Lexeo Therapeutics
LXEO
$259M
| $21.3M | 13.31% | 2,355,904 | – | – |
|
5
enGene Holdings
ENGN
$236M
| $7.1M | 4.44% | 1,076,357 | – | – |
|
|
ALMS
6
Alumis Inc. Common Stock
ALMS
$479M
| $6.98M | 4.36% | 653,223 -2 | -0% | -$21 |
|
|
IMA
7
ImageneBio, Inc. Common Stock
IMA
$150M
| $3.89M | 2.43% | 2,249,123 | – | – |
|
8
Sana Biotechnology
SANA
$777M
| $3.51M | 2.19% | 843,750 | – | – |
|
9
Immunic
IMUX
$80.9M
| $2.95M | 1.84% | 1,788,160 | – | – |
|
|
10
enGene Holdings Inc. Warrants
ENGNW
$7.08M
| $675K | 0.42% | 321,502 | – | – |
|
|
SYRS
11
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $540K | 0.34% | 251,270 | – | – |
|
|
MORF
12
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| – | – | -159,846 | Closed | -$5.45M |
|